1. AHRO : Austin Health Research Online
  2. Austin Health research
  3. Journal articles
Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/10959
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLuong, Jessica M T-
dc.contributor.authorTan, Boon T-
dc.contributor.authorBuchanan, Russell R C-
dc.contributor.authorSchachna, Lionel-
dc.date.accessioned2015-05-16T00:32:14Z-
dc.date.available2015-05-16T00:32:14Z-
dc.date.issued2010-02-02-
dc.identifier.citationClinical Rheumatology 2010; 29(5): 551-3en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/10959en
dc.description.abstractAn increase in reports of systemic lupus erythematosus (SLE) related to tumour necrosis factor inhibitor (TNFi) therapy has recently been highlighted. We report new-onset SLE in a 22-year-old woman after 13 months of infliximab for ankylosing spondylitis (AS). Lupus symptoms promptly resolved and serologic abnormalities improved after infliximab was ceased. A flare of AS symptoms after 2 months prompted cautious introduction of an alternative TNFi, etanercept. At 14 months follow-up, neither clinical nor serologic flare of lupus had occurred. To our knowledge, this is the third reported case of infliximab-related lupus that did not recur on switching to an alternative TNFi.en
dc.language.isoenen
dc.subject.otherAdulten
dc.subject.otherAntibodies, Monoclonal.pharmacologyen
dc.subject.otherAntirheumatic Agents.pharmacologyen
dc.subject.otherAutoimmunityen
dc.subject.otherDNA.metabolismen
dc.subject.otherFemaleen
dc.subject.otherHumansen
dc.subject.otherImmunoglobulin G.pharmacologyen
dc.subject.otherInflammationen
dc.subject.otherLupus Erythematosus, Systemic.blood.drug therapyen
dc.subject.otherQuality of Lifeen
dc.subject.otherReceptors, Tumor Necrosis Factoren
dc.subject.otherSpondylitis, Ankylosing.blood.drug therapyen
dc.subject.otherTime Factorsen
dc.subject.otherTumor Necrosis Factor-alpha.antagonists & inhibitorsen
dc.titleTumour necrosis factor inhibitor-related lupus: safety of switching agents.en
dc.typeJournal Articleen
dc.identifier.journaltitleClinical rheumatologyen
dc.identifier.affiliationRheumatologyen
dc.identifier.doi10.1007/s10067-009-1365-yen
dc.description.pages551-3en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/20119843en
dc.type.contentTexten
dc.type.austinJournal Articleen
local.name.researcherBuchanan, Russell R C
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.openairetypeJournal Article-
item.grantfulltextopen-
item.cerifentitytypePublications-
item.fulltextWith Fulltext-
item.languageiso639-1en-
crisitem.author.deptRheumatology-
crisitem.author.deptRheumatology-
Appears in Collections:Journal articles
Files in This Item:
File SizeFormat 
20119843.pdf43.12 kBAdobe PDFView/Open
Show simple item record

Page view(s)

38
checked on Oct 2, 2024

Download(s)

94
checked on Oct 2, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.